Brodalumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interleukin 17 receptor A |
| Clinical data | |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 1174395-19-7 |
| ATC code | None |
| KEGG | D10061  |
| Chemical data | |
| Formula | C6372H9840N1712O1988S52 |
| Mol. mass | 144.06 kDa |
| (what is this?) (verify) | |
Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1] It is being tested for the treatment of moderate to severe psoriasis[2] in Phase III clinical trials as of November 2013.[3][4]
Brodalumab was developed by Amgen, Inc.
Mechanism of action
Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.[2]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab". American Medical Association.
- ↑ 2.0 2.1 "Neue Antikörper in der Pipeline". Pharmazeutische Zeitung (in German) (12). 2012.
- ↑ ClinicalTrials.gov NCT01708590 Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)
- ↑ ClinicalTrials.gov NCT01708629 Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.